This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=101 http://www.lsis.com/goto/r101/rss 2012-02-05T11:11:04+01:00 text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 This review describes pharmacological studies showing that the dopamine D-1 receptor subtype is involved in the modulation of states of sleep and wakefulness. Stimulation of D-1 receptors by SKF 38393 produces electro encephalographic (EEG) arousal, enhances duration of wakefulness and markedly reduces the stage of rapid eye movement sleep (REM). Importantly, all these effects occur in the absence of the most typical dopamine- mediated behaviours such as stereotyped movements or hyperactivity. (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of golimumab (Schering-Plough/Centocor) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have responded inadequately to previous disease-modifying anti-rheumatic drugs (DMARDs). The Centre for Reviews and Dissemination and the Centre for Health Economics at the University of York were commissioned (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)- Positive Opinion Recommends Approval of the First and Only Anti-TNF Therapy in Pediatric Patients with Severely Active Ulcerative Colitis, a Chronic, Inflammatory Bowel Disease MSD (also known as Merck in the United States and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 Summary.? In chronic hepatitis C (CHC), treatment duration may be individualized according to time to first undetectable hepatitis C virus (HCV) RNA, with patients who attain undetectable HCV RNA early in treatment being candidates for shorter regimens. The aim of this study was to determine the relapse rate in patients with CHC genotype (G) 1 infection and low baseline viral load who achieved undetectable HCV RNA by week 4 [rapid virologic response (RVR)] when treated for 24?weeks. This (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 PATHOGENESIS AND TREATMENT: Conflict of interest: U. Beuers has received financial support for lecturing from the Falk Foundation, Gilead, Roche, Schering-Plough and Zambon and has received financial support for research from the German Crohn-Colitis Association, the Norwegian Primary Sclerosing Cholangitis Association and from Zambon. Financial support for this article: none declared. |-| Ned Tijdschr Geneeskd. |-| Kremer AE, Maillette de Buy Wenniger L, Oude Elferink RP, Beuers U. |-| Tytgat (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 ABSTRACT: Two randomized, double-blind, 26-week core studies (Eastern [EH] and Western Hemisphere [WH]) tested the hypothesis that asenapine is superior to olanzapine for persistent negative symptoms of schizophrenia; 26-week extension studies assessed the comparative long-term efficacy and safety of these agents. In the core studies, 949 people were randomized to asenapine (n = 241 and 244) or olanzapine (n = 240 and 224); 26-week completion rates with asenapine were 64.7% and 49.6% (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 ABSTRACT: In a 12-week randomized, placebo-controlled study evaluating the efficacy and safety of adjunctive asenapine, bipolar I disorder patients experiencing manic or mixed episodes despite pretreatment with lithium or valproate monotherapy were treated with flexible-dose, twice-daily asenapine 5 or 10 mg (n = 158) or placebo (n = 166). The primary efficacy end point was change from baseline Young Mania Rating Scale (YMRS) total score at week 3. Secondary outcomes included YMRS response and (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=101 United States Patent: 8084445 |-| Title: Pharmaceutical formulation |-| Inventors: Huq; Abu S (Plainsboro, NJ), Weingarten; Allan J (Westfield, NJ), Simmons; Robert D (Martinsville, NJ) |-| Assignee: Schering-Plough Animal Health Corporation (Union, NJ) |-| Disclosed are novel formulations for the treatment of otic infections in an animal comprising a triazole anti-fungal compound, a quinolone antibiotic and a corticosteroid such as mometasone furoate monohydrate. text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=101 ScienceDaily (Dec. 21, 2011) New research suggests that, in people who don't currently have memory problems, those with smaller regions of the brain's cortex may be more likely to develop symptoms consistent with very early Alzheimer's disease. The study is published in the December 21, 2011, online issue of Neurology , the medical journal of the American Academy of Neurology. See Also: Health & Medicine Alzheimer's Research Healthy Aging Cholesterol Mind & Brain Alzheimer's Dementia (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=101 CAMBRIDGE, Mass., December 13, 2011 ImmusanT, Inc. announced today it has raised $20 million in Series A financing from Vatera Healthcare Partners LLC to advance development of the biotechnology company s immunotherapeutic vaccine Nexvax2, companion diagnostic and monitoring tool for celiac disease. The proceeds will fund the Nexvax2 therapeutic and diagnostic development plan to the point of demonstrating proof-of-concept. ImmusanT expects to initiate the next clinical trial in early 2012. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, today announced the establishment of an Asia Research & Development (R&D) headquarters for innovative drug discovery and development located in Beijing, China. The new facility is part of a $1.5 billion commitment the company has made to invest in R&D in China over the next five years. "The establishment of the MSD Asia R&D headquarters represents an important milestone (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=101 PALO ALTO, CA-(Marketwire - December 05, 2011) - TOPICA Pharmaceuticals, Inc., a privately held biotechnology company, today announced that Amir Tavakkol, Ph.D., has joined the company as senior vice president of clinical development and operations. With 20 years of experience in the pharmaceutical industry, consumer healthcare and academia, Dr. Tavakkol will be responsible for advancing the clinical development of luliconazole, TOPICA's broad-spectrum topical antifungal agent, for the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J., Dec. 1, 2011 Today, on World AIDS Day, an expert panel of physicians from HIV clinics across the country announced the launch of the CALIBER (Clinic Activation to Lead and Implement Best practices for Enhancing Response to HIV) of Care © initiative, a partnership with Merck that is designed to help improve HIV patient care through physician-patient communication resources. Many people living with HIV in the United States seek medical care through local clinics, and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 Pharmacopsychiatry. |-| Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. |-| Schering-Plough (formerly NV Organon), now Merck Sharp & Dohme, Oss, The Netherlands. text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=101 ScienceDaily (Nov. 9, 2011) Data from the BRIDGE clinical trial demonstrate that intravenous use of the drug cangrelor was effective at maintaining platelet inhibition in patients on thienopyridines who required bypass surgery. Trial results were presented at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. See Also: Health & Medicine Heart Disease Today's Healthcare Wounds and Healing Pharmacology Skin (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Peter N. Kellogg, Merck's chief financial officer and Luciano Rossetti, M.D., Merck's senior vice president, Global Scientific Strategy, are scheduled to present at the 2011 Credit Suisse Healthcare Conference in Phoenix Nov. 11 at 9:00 a.m. MST (11:00 a.m. EST). Investors, analysts, members of the media and the general public are invited to listen to a live (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/0db780/the_pricing_and_re) has announced the addition of Decision Resources, Inc.'s new report "The Pricing and Reimbursement Environment for Respiratory Disease Therapies" to their offering. The Pricing and Reimbursement Environment for Respiratory Disease Therapies Common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) make up a large and varied pharmaceutical market (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (NYSE:MRK), known outside the United States and Canada as MSD, today is hosting a R&D and Business Briefing. We continue to make significant progress on our strategy to drive growth from our existing portfolio and to bring forward breakthrough medicines and vaccines that address unmet medical needs and return significant value to our shareholders. "Innovation is the centerpiece of our growth strategy at Merck," said Kenneth C. Frazier, president (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)- Merck (NYSE: MRK - News), known as MSD outside the United States and Canada, today is holding its R&D and Business Briefing at its global headquarters, highlighting the company's research strategy, including candidates from its R&D pipeline, and providing an update on its plans for growth. "Early in the year, we said 2011 would be all about executing our growth plans,  said Kenneth C. Frazier, president and chief executive officer, œand there can (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (known as MSD outside the United States and Canada) (NYSE: MRK) today announced that NEXPLANON (etonogestrel implant) 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States. NEXPLANON is approved by the FDA for the prevention of pregnancy in women for up to three years. NEXPLANON must be removed by the end of the third year and may be replaced by a new NEXPLANON, if continued contraceptive (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 SAN FRANCISCO-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results of an interim analysis from the PROVIDE study, an open-label study examining the efficacy of VICTRELIS ¢ (boceprevir), the company s first-in-class, oral hepatitis C virus (HCV) NS3/4A protease inhibitor, in combination with peginterferon alfa and ribavirin (P/R) in adult patients with chronic HCV genotype 1 who had a null response to prior P/R therapy. These (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) unanimously voted to recommend approval of Merck's VYTORIN (ezetimibe/simvastatin) for use in patients with pre-dialysis chronic kidney disease. The Committee's vote was mixed (with the majority not in favor) regarding whether there is sufficient evidence to (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 The macrocyclic lactone endectocides typified by ivermectin are safe and effective drugs when used according to label directions. However, off-label use, misuse and overdosing can result in toxicity in animal patients as revealed by pharmacovigilance activities. Preclinical toxicity studies demonstrates that the major clinical signs of toxicity are those associated with neurotoxic effects and these are the most common adverse drug reactions noted in overdosed treated animals. Subpopulations of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 HORSHAM, Pa.-(BUSINESS WIRE)-Galleon Pharmaceuticals, a leader in the pharmaceutical treatment of breathing-control disorders, announced today the appointments of D. Euan MacIntyre, Ph.D., as senior vice president, drug discovery, and James F. McLeod, M.D., as senior vice president, clinical research and development, and chief medical officer. James C. Mannion, Ph.D., Galleon s president, chief executive officer and founder, stated: œEuan and Jim are highly experienced scientists and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2011. Going forward, Merck will continue to implement our growth strategy, while transforming the way we operate our business $ in millions, except EPS amounts ThirdQuarter2011 ThirdQuarter2010 Sales $ 12,022 $ 11,125 GAAP EPS 0.55 0.11 Non-GAAP EPS that excludes items listed below 1 0.94 0.85 GAAP Net Income 2 1,692 342 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 PASADENA, Calif.-(BUSINESS WIRE)-Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it has appointed Bruce Given, M.D. to the position of Chief Operating Officer of the Company effective October 26, 2011. Since February 1, 2010, Dr. Given has served as Chief Executive Officer of Leonardo Biosystems, Inc., a company in which Arrowhead maintains a minority equity interest, and he also has served as a director of Calando Pharmaceuticals, Inc., a subsidiary of Arrowhead, since (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/3b5e71/mergers_and_acquis) has announced the addition of the "Mergers and Acquisitions in the Pharmaceuticals Sector, 2009: Critical Success Factors for Competing in a Consolidating Market" report to their offering. Mergers and Acquisitions in the Pharmaceuticals Sector, 2009: Critical Success Factors for Competing in a Consolidating Market Explores the merits of mega-deal in contrast to a more measured (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (known as MSD outside the United States and Canada) announced today that data from a sub-study of the pivotal Phase III clinical trial with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] in males were published in the October 27 issue of the New England Journal of Medicine (NEJM). In this study of 602 healthy men who have sex with men (MSM), ages 16 to 26 years, GARDASIL was 77.5 percent effective in (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention s (CDC s) Advisory Committee on Immunization Practices (ACIP) voted to recommend that boys 11 to 12 years old be vaccinated routinely with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] to help prevent anal cancer caused by human papillomavirus (HPV) types 16 and 18, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 CLIFFSIDE PARK, N.J. & KURUME, Japan-(BUSINESS WIRE)-Pop Test Cortisol LLC, under the umbrella of the POP Test companies, today announced pre-clinical trials in which the company has successfully demonstrated the efficacy of a chemotherapy sensitizer for œtriple negative  breast cancer. These are the most difficult to treat breast cancers, testing negative for estrogen-receptor, progesterone-receptor and her-2/neu and are resistant to chemotherapy. We are tremendously optimistic about the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 HONOLULU-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two 26-week investigational Phase III clinical studies evaluating the efficacy and safety of two dose strengths of DULERA (mometasone furoate and formoterol fumarate dihydrate) in adults 40 years and older with moderate to very severe chronic obstructive pulmonary disease (COPD). The two dose strengths evaluated in the studies were DULERA 100 mcg/5 mcg and DULERA 200 (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 BACKGROUND: Because women of childbearing potential represent 20% to 25% of the HIV population, it is important to determine any potential drug interactions between vicriviroc, an antiretroviral agent, and an oral contraceptive (OC) to provide guidance on any potential dose adjustments. OBJECTIVE: The primary study objective was to determine the effect of vicriviroc, a C-C chemokine receptor type 5 inhibitor, alone or in the presence of ritonavir, on the pharmacokinetics (AUC and C(max) of (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=101 ScienceDaily (Oct. 20, 2011) With age, forgetfulness and other signs of memory loss sometimes appear, prompting elderly individuals to seek a medical evaluation amid fears that they may be experiencing early symptoms of Alzheimer's disease (AD), the most common type of dementia among Americans aged 65 and older. See Also: Health & Medicine Alzheimer's Research Healthy Aging Chronic Illness Mind & Brain Alzheimer's Dementia Intelligence Reference Dementia Dementia with Lewy bodies Multi-infarct (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=101 With age, forgetfulness and other signs of memory loss sometimes appear, prompting elderly individuals to seek a medical evaluation amid fears that they may be experiencing early symptoms of Alzheimer's disease (AD), the most common type of dementia among Americans aged 65 and older. But even when early memory problems suggest the potential for impending AD, the actual risk is variable. Some patients are at high risk while others are not. The challenge for doctors has long been to (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=101 As part of a restructuring plan it announced four months ago, Merck said it will eliminate 50 jobs at a site in Springfield that it gained through a merger with Schering-Plough. In a notice filed with the state Department of Labor earlier this week, Merck said the job cuts would go into effect on Dec. 20. The notice did not describe the type of jobs Merck is cutting at the Lawrence Road office site, and Ron Rogers, a spokesman for the drug maker, said the company would not provide specific (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 BOSTON-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from a 24-week interim analysis of an ongoing 48-week Phase IIb clinical study evaluating the investigational use of VICTRELIS ¢ (boceprevir), the company s first-in-class, oral hepatitis C virus (HCV) NS3/4A protease inhibitor, in combination with peginterferon alfa and ribavirin for the treatment of chronic HCV genotype 1 infection in adult patients coinfected with (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=101 By Paul Koepp, Reporter - Kansas City Business Journal Two former employees of Lenexa-based Lee Research Institute have pleaded guilty to charges related to falsifying study data in a clinical drug trial. Dr. Wayne Spencer, 73, of Topeka, and Lisa Sharp, 48, of Olathe, pleaded guilty to conspiracy and failing to maintain records, the U.S. Attorney s Office for the District of Kansas said Wednesday. Each faces as much as five years in prison and a fine of $250,000 on the conspiracy charge, and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 RALEIGH, N.C.-(BUSINESS WIRE)-LipoScience, Inc., an in-vitro diagnostic company advancing patient care in cardiovascular, metabolic and other diseases using an innovative and proprietary platform based on Nuclear Magnetic Resonance (NMR) technology, today announced the appointment of Robert Honigberg, M.D. as Chief Medical Officer and Vice President, Medical Affairs. Dr. Honigberg s responsibilities will include the development and implementation of strategies for clinical trials, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 BELGRADE, Serbia-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK Phase III study of its integrase inhibitor ISENTRESS (raltegravir) Tablets in combination therapy compared to efavirenz in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients. The analyses showed that the regimen containing ISENTRESS demonstrated better (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 CHICAGO-(BUSINESS WIRE)-Fitch Ratings has affirmed Merck & Co., Inc.'s (Merck) ratings as follows: -Long-term Issuer Default Rating (IDR) at 'A+'; -Senior unsecured debt rating at 'A+'; -Bank loan rating at 'A+'; -Short-term IDR at 'F1'; -Commercial paper rating at 'F1'. The ratings apply to approximately $18.3 billion of debt. The Rating Outlook is Stable. Merck reduced its risk to key drug patent expiry through the long term with the research and diversified product portfolios gained (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC ¢(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR (simvastatin). JUVISYNC is the first treatment option for healthcare (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/71299c/top_100_pharmaceut) has announced the addition of Plimsoll Publishing Ltd.'s "Top 100 Pharmaceutical Manufacturers (Global)" report to their extensive range of pharmaceutical publications. The latest report from Plimsoll Publishing is an in-depth financial evaluation of the top 100 pharmaceutical companies in the world. Using the unique Plimsoll method of analysis, each of the global top 100 (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.-(BUSINESS WIRE)-Merck (NYSE:MRK), known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for ridaforolimus, an investigational oral mTOR inhibitor under development for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Richard T. Clark, chairman, will retire from the company and the Merck board of directors effective Dec. 1, 2011. Clark led the company for five years as president and chief executive officer from 2005 through 2010. He has served as a Merck director since May 2005 and chairman of its board of directors since 2007. In January 2011, Kenneth C. Frazier became (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 The enzyme protein farnesyltransferase (FPT) transfers a farnesyl group from the prenyl donor farnesyl diphosphate (FPP) to a cysteine residue on substrate proteins which contain a C-terminal CaaX motif, where C is cysteine, a is an aliphatic amino acid, and X is methionine, serine, or glutamine. Known substrates for FPT include nuclear lamin B and the small GTP-binding proteins H-, K-, and N-Ras. Short peptides encompassing the CaaX motif of these proteins are also farnesylated by FPT. In (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said a federal court jury in New York found in its favor in the Secrest v. Merck case, rejecting the claim of a Florida woman who blamed her dental and jaw-related problems on her FOSAMAX use. We have now won four of the first five cases that have been tried to verdict. We continue to believe that FOSAMAX is a safe and effective medication and the company provided appropriate (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 Protein tyrosine kinases (PTKs) are ubiquitous enzymes that are integrally involved in the regulation of transformation mechanisms, normal and pathological growth, cell cycle regulation, immune responses, and a variety of intracellular signaling mechanisms. This rapidly growing family of enzymes is generally divided into two groups: receptor PTKs (with more than twelve distinct families) and nonreceptor PTKs (with more than nine distinct families). PTKs mediate the enzymatic transfer of the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS ¢ (boceprevir), the company s first-in-class, oral hepatitis C virus (HCV) NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). The meeting will be held Nov. 4-8 in San Francisco. Presentations will include results (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=101 This unit describes essential procedures to record the activity of and the effects of pharmacological manipulation upon tetrodotoxin-resistant (TTXr) sodium channels. Readers are guided through the process of assembling a functional |patch-clamp| electrophysiology apparatus and construction of software-controlled voltage protocols that address various aspects of channel gating. Guidelines are also presented for analysis and display of the data typically generated by these experiments. For (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=101 WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck (NYSE:MRK), known outside the United States and Canada as MSD, today announced that the company has sold its 50 percent interest in the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. joint venture (JJMCP) to Johnson & Johnson (J&J) affiliates, McNEIL-PPC, Inc., McNEIL MMP, LLC, and Johnson & Johnson, Inc. The venture between Merck and J&J was formed in 1989 to develop, manufacture, market and distribute certain over-the-counter (OTC) (…)